Meeting
2023 ASCO Genitourinary Cancers Symposium
Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).
Presenter
Philippe Barthelemy, MD, PhD
Medical Oncology, Institut de Cancérologie Strasbourg Europe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Clinical Trial Registration Number
NCT04822350
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 471)
DOI
10.1200/JCO.2023.41.6_suppl.471
Abstract #
471
Poster Bd #
H12
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes.
Speaker: Yohann Loriot, MD, PhD
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Updated results from AVENANCE: Real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment.
Speaker: Philippe Barthelemy, MD, PhD
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI).
Speaker: Jeanny B. Aragon-Ching, MD, FACP
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term patient-reported outcomes (PROs) in the phase 3 JAVELIN Bladder 100 trial.
Speaker: Petros Grivas, MD, PhD